What Is Pegulicianine? Definition and What Research Reports

Definition

Pegulicianine is an injectable, protease-activated fluorescence imaging agent used during cancer surgery. Structurally it belongs to the family of "activatable" optical probes: a polyethylene glycol (PEG) scaffold carries a short peptide linker that is flanked by a near-infrared fluorophore and a quenching molecule. While the linker is intact, the quencher absorbs the dye's emission and the molecule remains optically dark; when tumour-associated proteases cleave the peptide linker, the fluorophore is separated from the quencher and the released fragment emits near-infrared light that a compatible imaging device can detect. In clinical research the agent has been administered intravenously before surgery and paired with a handheld imaging system that scans the walls of the surgical cavity. It is a diagnostic agent rather than a treatment — it is not intended to shrink, kill or modify tissue, only to generate a signal that surgeons and researchers can image.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about diagnosis, treatment or surgical care.

What Class of Molecule It Is and Where It Comes From

Pegulicianine is a synthetic, chemically manufactured conjugate rather than a naturally occurring hormone or a recombinant protein. Its three functional parts map onto three different chemistries:

• The PEG carrier — a polymer backbone that governs how long the agent circulates and how it distributes in tissue.
• The peptide linker — the short amino-acid sequence that acts as a protease substrate. This is the element that places pegulicianine inside the broader "peptide-based products" category used by regulators and by chemistry reviews.
• The fluorophore–quencher pair — a near-infrared dye and a matched quencher that keep the probe non-fluorescent until cleavage occurs.

Because of that peptide linker, pegulicianine is catalogued alongside other peptide and oligonucleotide products — the "TIDES" class — in regulatory-chemistry reviews; a 2025 review in Pharmaceuticals surveying the 2024 FDA harvest of peptide and oligonucleotide approvals included pegulicianine among the peptide-based agents cleared that year (PMID 40143070). In clinical use it has been supplied as a lyophilised powder for intravenous infusion and used together with a dedicated fluorescence imaging system; the drug and the device are treated as a combined system in the published trial literature.

How the Fluorescence Switch Is Described

The design logic reported in the surgical literature is that proteolytic enzyme activity is elevated in and around tumour tissue relative to normal tissue, so an agent that only lights up after protease cleavage should, in principle, produce contrast between residual tumour and surrounding tissue at the cut surface. The nonrandomized controlled trial published in JAMA Surgery in 2022 evaluated exactly that concept, describing the clinical impact of intraoperative margin assessment performed with a novel pegulicianine fluorescence-guided system during breast-conserving surgery (PMID 35544130).

How the Term Is Used in Peptide Research

Within peptide science, "pegulicianine" is most often cited as a worked example of two ideas rather than as a compound of interest in its own right:

1. Peptides as enzyme-specific triggers. The molecule is referenced when authors discuss protease-cleavable peptide linkers — the same design principle that underlies antibody–drug conjugate linkers and other activatable probes.
2. Peptide-containing products in the regulatory pipeline. Reviews that tally approved peptide and oligonucleotide products list pegulicianine as a peptide-based imaging agent, which is how it appeared in the 2025 Pharmaceuticals survey of 2024 FDA approvals (PMID 40143070).

It is worth separating pegulicianine from the research peptides that dominate general peptide discussion. It is not a growth-hormone secretagogue, not a metabolic peptide, and not sold or studied as a systemic therapy. Its literature sits in surgical oncology journals, not endocrinology ones.

What the Published Literature Reports

Breast-Conserving Surgery

The core body of evidence concerns lumpectomy margins. In the 2022 nonrandomized controlled trial published in JAMA Surgery, researchers assessed the clinical impact of adding pegulicianine fluorescence-guided margin assessment to standard breast-conserving surgery, with the practical question being whether imaging the cavity after the main specimen was removed changed what the surgical team did next (PMID 35544130). A subsequent trial report in NEJM Evidence in 2023 examined intraoperative fluorescence guidance for breast cancer lumpectomy surgery, evaluating the drug-plus-device system against standard lumpectomy practice (PMID 38320161). An accompanying NEJM Evidence editorial, titled "Something to Dye For: Toward Better Breast Lumpectomy Margins," discussed how such fluorescence approaches fit alongside existing intraoperative margin techniques and where the trade-offs lie between detecting residual disease and removing additional tissue (PMID 38320169).

Beyond Breast Cancer

Reported use outside breast surgery is so far limited to isolated cases. A 2026 report in Pediatric Blood & Cancer described what the authors characterised as the first pediatric use of pegulicianine for fluorescence-guided surgery, in a child with Li-Fraumeni-associated rhabdomyosarcoma (PMID 42488992). A single case report establishes feasibility in one patient and nothing more; it does not establish frequency of benefit, comparative performance, or generalisability to other tumour types.

Safety and Tolerability: What Studies Report

Safety information for pegulicianine comes from the surgical trials and the regulatory record rather than from any standalone toxicology literature summarised here. The 2022 JAMA Surgery nonrandomized controlled trial included safety monitoring alongside its assessment of intraoperative margin evaluation with the pegulicianine fluorescence-guided system (PMID 35544130), and the 2023 NEJM Evidence trial report of intraoperative fluorescence guidance in lumpectomy surgery likewise reported on participants who received the agent (PMID 38320161). The accompanying editorial framed the clinical question as a balance between improved detection and the burdens that come with any added intraoperative step, including drug administration itself (PMID 38320169). Readers looking for event-by-event frequencies should consult the full trial publications and the approved product labelling, which carry the primary safety data; this glossary entry does not reproduce numerical adverse-event rates.

Limits of the Current Evidence

• Narrow indication base. Nearly all published clinical data concern breast-conserving surgery in adults; the pediatric experience rests on a single reported case (PMID 42488992).
• Drug and device are inseparable. Results describe a system — the agent plus a specific imaging platform — so findings cannot be transferred to other fluorescence hardware.
• Operator and workflow dependence. Intraoperative imaging outcomes depend on how cavities are scanned and how signals are interpreted, a point raised in the editorial commentary on lumpectomy margins (PMID 38320169).
• Not a research peptide in the usual sense. Pegulicianine is a hospital-administered imaging agent used under surgical supervision, not a compound with a self-directed research literature.

Common Points of Confusion

Pegulicianine is sometimes grouped with fluorescence dyes such as indocyanine green. The distinction described in the design literature is that conventional dyes fluoresce continuously once injected, whereas pegulicianine is engineered to remain quenched until a peptide bond is cleaved by protease activity — an "activatable" rather than "always-on" probe. It is also distinct from radiotracers used in nuclear imaging: the signal is optical, near-infrared light detected by a camera in the operating field, not ionising radiation. Finally, the trade name of the marketed product and the generic name of the molecule refer to the same active agent, which is why both appear across the trial reports and the peptide-approval review (PMID 40143070).

References

• Clinical Impact of Intraoperative Margin Assessment in Breast-Conserving Surgery With a Novel Pegulicianine Fluorescence-Guided System: A Nonrandomized Controlled Trial (JAMA Surgery, 2022)
• Intraoperative Fluorescence Guidance for Breast Cancer Lumpectomy Surgery (NEJM Evidence, 2023)
• Something to Dye For: Toward Better Breast Lumpectomy Margins (NEJM Evidence, 2023)
• 2024 FDA TIDES (Peptides and Oligonucleotides) Harvest (Pharmaceuticals, 2025)
• First Pediatric Use of Pegulicianine for Fluorescence-Guided Surgery in Li-Fraumeni-Associated Rhabdomyosarcoma (Pediatric Blood & Cancer, 2026)